🇺🇸 FDA
Pipeline program

NPC-1C/NEO-102

Neogenix 0901

Phase 2 small_molecule completed

Quick answer

NPC-1C/NEO-102 for Metastatic Pancreatic Cancer is a Phase 2 program (small_molecule) at PRECISION BIOSCIENCES INC with 1 ClinicalTrials.gov record(s).

Program details

Company
PRECISION BIOSCIENCES INC
Indication
Metastatic Pancreatic Cancer
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials